0.7849 0.044 (5.88%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 1.08 | 1-year : | 1.27 |
Resists | First : | 0.92 | Second : | 1.09 |
Pivot price | 0.77 ![]() |
|||
Supports | First : | 0.66 | Second : | 0.54 |
MAs | MA(5) : | 0.73 ![]() |
MA(20) : | 0.79 ![]() |
MA(100) : | 1.1 ![]() |
MA(250) : | 1.59 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 18.9 ![]() |
D(3) : | 12.7 ![]() |
RSI | RSI(14): 50.4 ![]() |
|||
52-week | High : | 3.73 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LXRX ] has closed below upper band by 47.3%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.83 - 0.83 | 0.83 - 0.83 |
Low: | 0.74 - 0.75 | 0.75 - 0.75 |
Close: | 0.78 - 0.78 | 0.78 - 0.79 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Tue, 07 Jan 2025
Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Mon, 06 Jan 2025
Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Yahoo Finance
Fri, 20 Dec 2024
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan
Mon, 25 Nov 2024
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December - StockTitan
Fri, 22 Nov 2024
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 361 (M) |
Held by Insiders | 1.8214e+008 (%) |
Held by Institutions | 1.1 (%) |
Shares Short | 31,280 (K) |
Shares Short P.Month | 0 (K) |
EPS | -2.1055e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 639.5 % |
Return on Equity (ttm) | -44.2 % |
Qtrly Rev. Growth | 5.23e+006 % |
Gross Profit (p.s.) | 790.48 |
Sales Per Share | -109.75 |
EBITDA (p.s.) | -5.45726e+007 |
Qtrly Earnings Growth | -0.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 1.98 |
Dividend | 0 |
Forward Dividend | 3.91e+007 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |